Get the Stockscreener App
1.67
1.18%
-0.02
After Hours:
1.67
Century Therapeutics Inc stock is traded at $1.67, with a volume of 456.96K.
It is down -1.18% in the last 24 hours and down -23.04% over the past month.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
See More
Previous Close:
$1.69
Open:
$1.7
24h Volume:
456.96K
Relative Volume:
0.45
Market Cap:
$302.40M
Revenue:
$109.16M
Net Income/Loss:
$-107.78M
P/E Ratio:
-1.5095
EPS:
-1.1063
Net Cash Flow:
$-95.45M
1W Performance:
-10.22%
1M Performance:
-23.04%
6M Performance:
-19.32%
1Y Performance:
+242.42%
1-Day Range:
$1.63
$1.78
1-Week Range:
$1.63
$1.94
52-Week Range:
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
1.67 | 302.40M | 109.16M | -107.78M | -95.45M | -1.1063 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | TD Cowen | Buy |
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Form 144 Century Therapeutics For: 25 September By Investing.com - Investing.com Canada
Century Therapeutics stock falls 6.88 percent as milestones approach - AD HOC NEWS
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to S&P Global BMI Index - marketscreener.com
Century Therapeutics stock extends strong run as IPSC jumps over 700 percent in 12 months - AD HOC NEWS
Century Therapeutics stock falls as IPSC trades near 52-week low - AD HOC NEWS
Russotti Gregory Disposes 2,587 Shares of Century Therapeutics (NASDAQ: IPSC) at $1.93 Each - Kalkine Media
Century Therapeutics SVP Douglas Carr sells $3,199 in shares By Investing.com - Investing.com South Africa
Century Therapeutics SVP Douglas Carr sells $3,199 in shares - Investing.com
Century Therapeutics (IPSC) exec sale covers RSU taxes - Stock Titan
Century Therapeutics (IPSC) CEO holds 3,633,839 shares after tax move - Stock Titan
Century Therapeutics (IPSC) insider sale only covers tax withholding - Stock Titan
Century Therapeutics (NASDAQ: IPSC) officer intends $4,994 sale of stock - Stock Titan
Century Therapeutics (NASDAQ: IPSC) officer lines up 1,658-share stock sale - Stock Titan
LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Century Therapeutics (IPSC) awards 148,000 options vesting over 3 years - Stock Titan
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline - The Globe and Mail
Century Therapeutics' SVP Finance Carr Douglas Sells 254 Shares at $2.05 Each (NASDAQ: IPSC) - Kalkine Media
Century Therapeutics (NASDAQ: IPSC) Insider Russotti Gregory Sells 534 Shares, Retains 511,785 Shares - Kalkine Media
Century Therapeutics SVP sells $520 in stock for tax withholding By Investing.com - Investing.com Australia
Century Therapeutics appoints iECURE CEO Joseph Truitt to board - Bitget
Century Therapeutics Adds Joseph Truitt to Board of Directors - Minichart
Century Therapeutics CEO Brent Pfeiffenberger Withholds Shares for Tax on RSU Vesting - Kalkine Media
Century Therapeutics CTO Gregory Russotti Executes Automatic Sale of 534 Shares for Tax Withholding - Kalkine Media
Century Therapeutics appoints Joseph Truitt to board By Investing.com - Investing.com Nigeria
Century Therapeutics SVP sells $520 in stock for tax withholding - Investing.com
Century Therapeutics (IPSC) CEO shares withheld for taxes on RSU vesting - Stock Titan
Tax-withholding sale trims Century Therapeutics (NASDAQ: IPSC) insider by 534 shares - Stock Titan
Automatic tax sale leaves Century Therapeutics (NASDAQ: IPSC) SVP with 504,565 shares - Stock Titan
Century Therapeutics adds director, sets 2026 trial timelines - Stock Titan
Century Therapeutics appoints Joseph Truitt to board - Investing.com
Century Therapeutics Appoints Joseph Truitt to Board of Directors - Yahoo Finance UK
Century Therapeutics (NASDAQ: IPSC) officer plans stock sale partly to cover taxes - Stock Titan
Century (IPSC) Range: Rises 2.66% to $2.12 in the Latest Reading; Price Setup: the Supplied Trading Band Runs From $2.01 to $2.23 in the Latest SessionDynamic Hedging - careplusvn.com
Century (IPSC) Earnings Reading: EPS Beats Its Estimate at the Close; Share Move: The Stock Records a 4.27% Decrease in Latest TradingGuidance vs Actual - vinanet.vn
Century Targets FDA Filing for Diabetes Cell Therapy - MyChesCo
Century Therapeutics CEO Brent Pfeiffenberger Completes RSU Tax Withholding Share Transaction - Kalkine Media
Century Therapeutics (IPSC) CEO stock withheld for taxes - Stock Titan
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
HC Wainwright Issues Pessimistic Forecast for IPSC Earnings - MarketBeat
IPSC Q1 2026 Earnings: Narrower-Than-Expected Loss Yields 31.76% EPS SurpriseMid-Term Outlook - vinanet.vn
TD Cowen Maintains Century Therapeutics(IPSC.US) With Buy Rating - Moomoo
Century Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Century Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Century Therapeutics (NASDAQ:IPSC) Issues Quarterly Earnings Results - MarketBeat
Century Therapeutics Announces Q2 2026 Financial Results and Updates Investor Presentation in 8-K Filing - Kalkine Media
Form 8K Century Therapeutics Inc For: 12 August - Investing.com India
Century Therapeutics Reports Q2 Results, Pipeline Advancements - TipRanks
Form 8K Century Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Century Therapeutics posts $34.6 million Q2 loss as cash runway reaches 2029 - Quiver Quantitative
Century Therapeutics 2Q 2026: Revenue $0 EPS $(0.17) — 10-Q Summary - TradingView
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):